Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma
| Autor: | Dimitrios T. Trafalis, Nikolaos M. Sitaras, Athanassios E. Athanassiou, Constantinos Alifieris, Dimitrios Krikelis, Nikolaos Tzogkas, George P. Stathopoulos |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Male Mesothelioma medicine.medical_specialty medicine.medical_treatment Pleural Neoplasms Chest pain Polyethylene Glycols Quality of life Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Respiratory function Aged Pharmacology Cisplatin Chemotherapy business.industry Palliative Care Middle Aged Regimen Pemetrexed Doxorubicin Topotecan Female medicine.symptom business medicine.drug |
| Zdroj: | International journal of clinical pharmacology and therapeutics. 50(7) |
| ISSN: | 0946-1965 |
| Popis: | BACKGROUND Malignant pleural mesothelioma (MPM) is an aggressive disease with poor or modest responses to chemotherapy and dismal prognosis. In most of the cases the scope of the treatment is only palliative. In the current study, the combination of i.v. topotecan and pegylated liposomal doxorubicin (PLD) in advanced multi-treated MPM was tested. Primary objective was palliation of the symptoms, with the secondary ones being the establishment of the regimen's safety and efficacy. PATIENTS AND METHODS Nine patients were enrolled (7 males/2 females, median age 57.5 years, ECOG performance status ≤ 2), having progressed after 2 or 3 lines of chemotherapy including pemetrexed and cisplatin. Main symptoms were dyspnea, cough, chest pain, fatigue, and anorexia. The treatment included topotecan 1.2 mg/m2 i.v. on Days 1 - 3 and PLD 40 mg/m2 on Day 4, every 28 days. The patients received 4 - 8 chemotherapy cycles (median 5.8). RESULTS In all cases, symptoms were significantly improved after the 2nd treatment cycle. Respiratory function tests showed considerable enhancement, while cough and pain were drastically reduced. All patients had objective clinical benefit, 1 patient achieving partial response and 8 stable disease. Median time to progression and overall survival was 7 and 9 months, respectively. The chosen dose of the topotecan/ PLD combination was well-tolerated with no Grade 3/4 toxicities. Quality of life, as it was evaluated by the QLQ-C30 and QLQLC13 questionnaires, had improved scores especially the ones referring symptomatology. CONCLUSION The current study shows a significant palliative effect of the topotecan/ PLD combination in pretreated patients with advanced MPM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|